정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2172 | Recruiting | Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 | Thrombosis | Drug: Apixaban 2.5 MG Drug: Placebo |
Phase 4 | Brazilian Clinical Research Institute, Hospital Israelita Albert Einstein, Hospital do Coracao, Hospital Sirio-Libanes, Hospital Moinhos de Vento, Hospital Alemao Oswaldo Cruz, Beneficencia Portuguesa de Sao Paulo, Brazilian Research In Intensive Care Network | OTHER | 1000 | All | 18 Years | Hospital Maternidade Sao Vicente de Paulo, Barbalha, Ceara, Brazil Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil Hospital Universitario Sao Francisco de Assis, Braganca Paulista, Sao Paulo, Brazil Hospital Santa Paula, Sao Paulo, Brazil |
2171 | Not yet recruiting | Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 | Coronavirus Disease (COVID-19) | Biological: intradermal injection of BCG Vaccine Other: placebo |
Phase 3 | Ain Shams University | OTHER | 900 | All | 18 Years | Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt |
2170 | Not yet recruiting | Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness | COVID-19 Convalescent Plasma Treatment | Biological: COVID-19 convalescent plasma treatment | Not Applicable | Wroclaw Medical University, Medical Research Agency | OTHER | 500 | All | 18 Years | Wroclaw Medical University, Wroclaw, Dolno?l?skie, Poland |
2169 | Recruiting | Application of Desferal to Treat COVID-19 | COVID-19 | Drug: Deferoxamine | Phase 2 | Kermanshah University of Medical Sciences | OTHER | 50 | All | 3 Years ~ 99 Years | Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of |
2168 | Terminated | Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | COVID-19 | Drug: Aprepitant injectable emulsion Drug: Saline Placebo |
Phase 2 | Heron Therapeutics | INDUSTRY | 27 | All | 18 Years | Helen Keller Hospital, Sheffield, Alabama, United States University of California, Irvine Medical Center, Orange, California, United States Yale University School of Medicine, New Haven, Connecticut, United States |
2167 | Completed | APT™ T3X on the COVID-19 Contamination Rate | COVID-19 | Drug: Tetracycline hydrochloride 3% Drug: Placebo |
Not Applicable | University of Nove de Julho, Santa Casa de Misericordia de Porto Alegre | OTHER | 100 | All | 18 Years | Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil |
2166 | Withdrawn | Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection | Pneumonia, Viral | Drug: alpha1-proteinase inhibitor Drug: Antiviral Agents |
Phase 3 | Blessing Corporate Services, Inc, Takeda Pharmaceuticals North America, Inc. | OTHER | 0 | All | 18 Years | Blessing Corporate Services, Inc, Hannibal, Missouri, United States |